Comparative Pharmacology
Head-to-head clinical analysis: R P MYCIN versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: R P MYCIN versus WYAMYCIN S.
R-P MYCIN vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic